Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
REVUFORJ: Early FDA Approval Boosts Market Confidence and Buy Rating
BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...
Medscape5h
Revumenib Approved for R/R Acute Leukemia With KMT2A Translocation
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
FDA approves Syndax’s Revuforj to treat leukaemia
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
crypto2community18h
Best Cardano Coins That Could 100X This Week
MELD’s market cap is at $2.3 million. Revuto (REVU) is up 27.9% today and shows the potential for a skyrocketing week. Last ...
STAT18h
Syndax wins U.S. approval for leukemia treatment
The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...